©The Author(s) 2018.
World J Psychiatr. Mar 22, 2018; 8(1): 27-32
Published online Mar 22, 2018. doi: 10.5498/wjp.v8.i1.27
Published online Mar 22, 2018. doi: 10.5498/wjp.v8.i1.27
Table 1 Baseline characteristics of the audit sample (n = 30)
| Variable | Mean | SD |
| Age (yr) | 13.45 | 1.23 |
| Duration of antipsychotic use (mo) | 15.67 | 1.98 |
| Average number of clinical reviews | 3.43 | 0.46 |
| Variable | n | % |
| Age groups (yr) | ||
| 12-17 | 17 | 56.67 |
| < 12 | 13 | 43.33 |
| Gender | ||
| Male | 28 | 93.33 |
| Female | 2 | 6.67 |
| Antipsychotic | ||
| Risperidone | 23 | 76.67 |
| Aripiprazole | 7 | 23.33 |
| Psychiatric diagnosis | ||
| ADHD | 12 | 40.00 |
| ASD | 4 | 13.33 |
| ADHD + ASD | 6 | 20.00 |
| ADHD + other diagnosis | 6 | 20.00 |
| ASD + other diagnosis | 2 | 6.67 |
- Citation: Gnanavel S, Hussain S. Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World J Psychiatr 2018; 8(1): 27-32
- URL: https://www.wjgnet.com/2220-3206/full/v8/i1/27.htm
- DOI: https://dx.doi.org/10.5498/wjp.v8.i1.27